Class IA phosphatidylinositol 3-kinase inhibition inhibits cell growth and proliferation in mantle cell lymphoma

Acta Haematologica

Volumn 131, Issue 1, 2013, Pages 59-69

  Tabe, Yoko ^a   Jin, Linhua ^a   Konopleva, Marina ^d   Shikami, Masato ^c   Kimura, Shinya ^b   Andreeff, Michael ^d   Raffeld, Mark ^e   Miida, Takashi ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAGA UNIVERSITY   (Japan)

^c AICHI MEDICAL UNIVERSITY   (Japan)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Akt; BCR signaling; Class IA phosphatidylinositol 3 kinase; Mantle cell lymphoma

Indexed keywords

PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PICTILISIB; PROTEIN KINASE B; S6 KINASE; 2-(1H-INDAZOL-4-YL)-6-(4-METHANESULFONYLPIPERAZIN-1-YLMETHYL)-4-MORPHOLIN-4-YLTHIENO(3,2-D)PYRIMIDINE; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; CHROMONE DERIVATIVE; INDAZOLE DERIVATIVE; MORPHOLINE DERIVATIVE; PYRIMIDINONE DERIVATIVE; SULFONAMIDE; TGX 221; 2 (6 AMINO 9 PURINYLMETHYL) 5 METHYL 3 (2 METHYLPHENYL) 3H QUINAZOLIN 4 ONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 5 (6 QUINOXALINYLMETHYLENE) 2,4 THIAZOLIDINEDIONE; PROTEIN; S6K PROTEIN; UNCLASSIFIED DRUG; 2 (1H INDAZOL 4 YL) 6 (4 METHANESULFONYLPIPERAZIN 1 YLMETHYL) 4 MORPHOLIN 4 YLTHIENO(3,2 D)PYRIMIDINE; 9 (1 ANILINOETHYL) 7 METHYL 2 MORPHOLINOPYRIDO[1,2 A]PYRIMIDIN 4 ONE;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE ARREST; CELL VIABILITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; MANTLE CELL LYMPHOMA; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECTS; HUMAN; LYMPHOMA, MANTLE-CELL; METABOLISM; PATHOLOGY; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL DEATH; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN CELL; MANTLE CELL LYMPHOMA CELL; MTS ASSAY; SIGNAL TRANSDUCTION; DRUG ANTAGONISM; DRUG EFFECT;

CELL CYCLE; CELL PROLIFERATION; CHROMONES; CLASS IA PHOSPHATIDYLINOSITOL 3-KINASE; HUMANS; INDAZOLES; LYMPHOMA, MANTLE-CELL; MORPHOLINES; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINONES; SULFONAMIDES;

EID: 84890963163     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000353164     Document Type: Article

References (35)

1. Jares P, Colomer D, Campo E: Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 2007; 7: 750-762.
2. Quintanilla-Martinez L, Davies-Hill T, Fend F, Calzada-Wack J, Sorbara L, Campo E, Jaffe ES, Raffeld M: Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphoma (MCL): implications for pathogenesis. Blood 2003; 101: 3181-3187.
3. Bodrug SE, Warner BJ, Bath ML, Lindeman GJ, Harris AW, Adams JM: Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. EMBO J 1994; 13: 2124-2130.
4. Dal Col J, Zancai P, Terrin L, Guidoboni M, Ponzoni M, Pavan A, Spina M, Bergamin S, Rizzo S, Tirelli U, De Rossi A, Doglioni C, Dolcetti R: Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma. Blood 2008; 111: 5142-5151.
5. Rudelius M, Pittaluga S, Nishizuka S, Pham TH, Fend F, Jaffe ES, Quintanilla-Martinez L, Raffeld M: Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood 2006; 108: 1668- 1676.
6. Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, Laurell A, Offner F, Strahs A, Berkenblit A, Hanushevsky O, Clancy J, Hewes B, Moore L, Coiffier B: Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27: 3822-3829.
7. Vivanco I, Sawyers CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501.
8. Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ, Waterfield MD, Downward J: Phosphatidylinositol- 3-OH kinase as a direct target of Ras. Nature 1994; 370: 527-532.
9. Vanhaesebroeck B, Welham MJ, Kotani K, Stein R, Warne PH, Zvelebil MJ, Higashi K, Volinia S, Downward J, Waterfield MD: P110delta, a novel phosphoinositide 3-kinase in leukocytes. Proc Natl Acad Sci USA 1997; 94: 4330-4335.
10. Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, Xu W, Shaffer AL, Wright G, Xiao W, Powell J, Jiang JK, Thomas CJ, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Johnson NA, Rimsza LM, Campo E, Jaffe ES, Wilson WH, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pierce SK, Staudt LM: Chronic active B-cellreceptor signalling in diffuse large B-cell lymphoma. Nature 2010; 463: 88-92.
11. Ramadani F, Bolland DJ, Garcon F, Emery JL, Vanhaesebroeck B, Corcoran AE, Okkenhaug K: The PI3K isoforms p110alpha and p110delta are essential for pre-B cell receptor signaling and B cell development. Sci Signal 2010; 3:ra60.
12. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE: High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304: 554.
13. Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH, Zhang J, Signoretti S, Loda M, Roberts TM, Zhao JJ: Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 2008; 454: 776-779.
14. Rommel C, Camps M, Ji H: PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat Rev Immunol 2007; 7: 191-201.
15. Del Prete A, Vermi W, Dander E, Otero K, Barberis L, Luini W, Bernasconi S, Sironi M, Santoro A, Garlanda C, Facchetti F, Wymann MP, Vecchi A, Hirsch E, Mantovani A, Sozzani S: Defective dendritic cell migration and activation of adaptive immunity in PI3Kgamma- deficient mice. EMBO J 2004; 23: 3505- 3515.
16. Hu L, Zaloudek C, Mills GB, Gray J, Jaffe RB: In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res 2000; 6: 880-886.
17. Kong D, Yamori T: Advances in development of phosphatidylinositol 3-kinase inhibitors. Curr Med Chem 2009; 16: 2839-2854.
18. Jadayel DM, Lukas J, Nacheva E, Bartkova J, Stranks G, De Schouwer PJ, Lens D, Bartek J, Dyer MJ, Kruger AR, Catovsky D: Potential role for concurrent abnormalities of the cyclin D1, p16CDKN2 and p15CDKN2B genes in certain B cell non-Hodgkin's lymphomas. Functional studies in a cell line (Granta 519). Leukemia 1997; 11: 64-72.
19. Melo JV, Brito-Babapulle V, Foroni L, Robinson DS, Luzzatto L, Catovsky D: Two new cell lines from B-prolymphocytic leukaemia: characterization by morphology, immunological markers, karyotype and Ig gene rearrangement. Int J Cancer 1986; 38: 531-538.
20. Jeon HJ, Kim CW, Yoshino T, Akagi T: Establishment and characterization of a mantle cell lymphoma cell line. Br J Haematol 1998; 102: 1323-1326.
21. Tabe Y, Konopleva M, Munsell MF, Marini FC, Zompetta C, McQueen T, Tsao T, Zhao S, Pierce S, Igari J, Estey EH, Andreeff M: PMLRARalpha is associated with leptin-receptor induction: the role of mesenchymal stem cellderived adipocytes in APL cell survival. Blood 2004; 103: 1815-1822.
22. Feng Z, Hu W, de Stanchina E, Teresky AK, Jin S, Lowe S, Levine AJ: The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer Res 2007; 67: 3043-3053.
23. Fan QW, Knight ZA, Goldenberg DD, Yu W, Mostov KE, Stokoe D, Shokat KM, Weiss WA: A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 2006; 9: 341-349.
24. Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box B, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl- Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ: The identification of 2-(1H-indazol- 4-yl)-6-(4-methanesulfonyl-piperazin- 1-ylmethyl)-4-morpholin-4-yl-thieno [3,2-d] pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem 2008; 51: 5522-5532.
25. Niedermeier M, Hennessy BT, Knight ZA, Henneberg M, Hu J, Kurtova AV, Wierda WG, Keating MJ, Shokat KM, Burger JA: Isoform- selective phosphoinositide 3 ′ -kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood 2009; 113: 5549- 5557.
26. Psyrri A, Papageorgiou S, Liakata E, Scorilas A, Rontogianni D, Kontos CK, Argyriou P, Pectasides D, Harhalakis N, Pappa V, Kolialexi A, Economopoulou C, Kontsioti F, Maratou E, Dimitriadis G, Economopoulou P, Economopoulos T: Phosphatidylinositol 3 ′ -kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma. Clin Cancer Res 2009; 15: 5724-5732.
27. Jou ST, Carpino N, Takahashi Y, Piekorz R, Chao JR, Wang D, Ihle JN: Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex. Mol Cell Biol 2002; 22: 8580- 8591.
28. Bilancio A, Okkenhaug K, Camps M, Emery JL, Ruckle T, Rommel C, Vanhaesebroeck B: Key role of the p110delta isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110delta function in B cells. Blood 2006; 107: 642-650.
29. Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ: Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2010; 116: 2078-2088.
30. Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B, Johnson AJ, Byrd JC, Tyner JW, Loriaux MM, Deininger M, Druker BJ, Puri KD, Ulrich RG, Giese NA: CAL- 101, a p110delta selective phosphatidylinositol- 3-kinase inhibitor for the treatment of Bcell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011; 117: 591-594.
31. Weiss WA, Taylor SS, Shokat KM: Recognizing and exploiting differences between RNAi and small-molecule inhibitors. Nat Chem Biol 2007; 3: 739-744.
32. Gururajan M, Jennings CD, Bondada S: Cutting edge: constitutive B cell receptor signaling is critical for basal growth of B lymphoma. J Immunol 2006; 176: 5715-5719.
33. Rinaldi A, Kwee I, Taborelli M, Largo C, Uccella S, Martin V, Poretti G, Gaidano G, Calabrese G, Martinelli G, Baldini L, Pruneri G, Capella C, Zucca E, Cotter FE, Cigudosa JC, Catapano CV, Tibiletti MG, Bertoni F: Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br J Haematol 2006; 132: 303- 316.
34. Limon JJ, Fruman DA: B cell receptor signaling: picky about PI3Ks. Sci Signal 2010; 3: pe25.
35. de Frias M, Iglesias-Serret D, Cosialls AM, Coll-Mulet L, Santidrian AF, Gonzalez-Girones DM, de la Banda E, Pons G, Gil J: Akt inhibitors induce apoptosis in chronic lymphocytic leukemia cells. Haematologica 2009; 94: 1698-1707.